Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company is sponsoring university research on light waves reacting in characteristic patterns for de… https://t.co/RG11kdD0as
    about 15 hours ago
  • New post on Science and Enterprise: Univ Lab, Company Developing Phone-Based Virus Sensor https://t.co/Yqq5wZPmqF #Science #Business
    about 15 hours ago
  • A blood test designed for low-resource field settings is shown to quickly detect and distinguish between different… https://t.co/7RCwijmW7N
    about 21 hours ago
  • New post on Science and Enterprise: Quick Crispr-Based Test Detects Malaria in Blood https://t.co/LuZnLHRUYW #Science #Business
    about 21 hours ago
  • Researchers in the U.K. created a bandage with enhanced human skeletal stem cells that in lab mice repairs simulate… https://t.co/1tD7FxaoRo
    about 2 days ago

Please share Science & Enterprise

Covid-19 Vaccines, Therapies – 20 July 2020

Covid-19 vaccines and therapies

BioRender Covid-19 vaccine and therapy tracker. (BioRender.com)

20 July 2020. A continuing feature on Science & Enterprise is a weekly statistical report of vaccines and therapies for Covid-19 offered by BioRender, a scientific illustration software company. BioRender, in Toronto, Ontario, develops graphics tools for life sciences, biotechnology, and other disciplines.

This week, the data show a sharp jump in new Covid-19 therapy projects, with 17 new treatments reported raising the total to 322. Two more of those therapies reached clinical trial stage last week, raising that number to 236. Likewise, two more Covid-19 vaccine initiatives are underway with now two more vaccines also in clinical trials, increasing those totals to 155 and 31 respectively.

In addition to the summary dashboard shown above, the BioRender Covid-19 vaccine and therapy page provides details of the vaccines and therapies, as well as an activity feed showing news updates on these drugs.

Last week, Science & Enterprise reported on some of those new vaccine and therapy developments. One story tells about preclinical tests of a new vaccine administered as a nasal spray, which according to its developer Altimmune Inc., invokes multiple immune responses. In another story last week, Adagio Therapeutics, a new company, is raising $50 million in venture capital for its engineered therapies to act against a range of coronaviruses, not just Covid-19.

More from Science & Enterprise:

*     *     *

1 comment to Covid-19 Vaccines, Therapies – 20 July 2020